Does the media refer more to VTGN or ONCY?

In the previous week, VistaGen Therapeutics and VistaGen Therapeutics both had 2 articles in the media. VistaGen Therapeutics' average media sentiment score of 0.93 equaled Oncolytics Biotech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer FTLF or VTGN?

In the previous week, FitLife Brands had 3 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 5 mentions for FitLife Brands and 2 mentions for VistaGen Therapeutics. FitLife Brands' average media sentiment score of 1.01 beat VistaGen Therapeutics' score of 0.93 indicating that FitLife Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FitLife Brands 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VTGN or ANIX?

In the previous week, Anixa Biosciences had 2 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 4 mentions for Anixa Biosciences and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.93 beat Anixa Biosciences' score of 0.91 indicating that VistaGen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anixa Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer VTGN or TELO?

VistaGen Therapeutics presently has a consensus price target of $0.95, indicating a potential upside of 35.33%. Given VistaGen Therapeutics' higher possible upside, equities research analysts clearly believe VistaGen Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor VTGN or TELO?

In the previous week, VistaGen Therapeutics and VistaGen Therapeutics both had 2 articles in the media. Telomir Pharmaceuticals' average media sentiment score of 1.31 beat VistaGen Therapeutics' score of 0.93 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telomir Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

VistaGen Therapeutics (VTGN) Competitors

$0.70 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$0.76 +0.06 (+8.26%)

As of 05:41 AM Eastern

Compare

VTGN vs. ONCY, AADI, FTLF, ANIX, and TELO

Should you buy VistaGen Therapeutics stock or one of its competitors? MarketBeat compares VistaGen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VistaGen Therapeutics include Oncolytics Biotech (ONCY), Aadi Bioscience (AADI), FitLife Brands (FTLF), Anixa Biosciences (ANIX), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry.

How does VistaGen Therapeutics compare to Oncolytics Biotech?

VistaGen Therapeutics (NASDAQ:VTGN) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Oncolytics Biotech has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

VistaGen Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Oncolytics Biotech has lower revenue, but higher earnings than VistaGen Therapeutics. Oncolytics Biotech is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	22.68	-$69.68M	-$1.83	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

In the previous week, VistaGen Therapeutics and VistaGen Therapeutics both had 2 articles in the media. VistaGen Therapeutics' average media sentiment score of 0.93 equaled Oncolytics Biotech'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

VistaGen Therapeutics currently has a consensus price target of $0.95, suggesting a potential upside of 35.33%. Oncolytics Biotech has a consensus price target of $8.50, suggesting a potential upside of 796.81%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Oncolytics Biotech beats VistaGen Therapeutics on 8 of the 14 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Aadi Bioscience?

VistaGen Therapeutics (NASDAQ:VTGN) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, VistaGen Therapeutics had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 0 mentions for Aadi Bioscience. VistaGen Therapeutics' average media sentiment score of 0.93 beat Aadi Bioscience's score of 0.00 indicating that VistaGen Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
VistaGen Therapeutics	Positive
Aadi Bioscience	Neutral

Aadi Bioscience has higher revenue and earnings than VistaGen Therapeutics. Aadi Bioscience is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	22.68	-$69.68M	-$1.83	N/A
Aadi Bioscience	$25.07M	4.10	-$65.76M	-$2.35	N/A

Aadi Bioscience has a net margin of -246.06% compared to VistaGen Therapeutics' net margin of -5,487.01%. Aadi Bioscience's return on equity of -71.87% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

VistaGen Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

VistaGen Therapeutics currently has a consensus price target of $0.95, indicating a potential upside of 35.33%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe VistaGen Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

VistaGen Therapeutics beats Aadi Bioscience on 8 of the 15 factors compared between the two stocks.

How does VistaGen Therapeutics compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

FitLife Brands has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.28	$6.33M	$0.60	18.47
VistaGen Therapeutics	$1.27M	22.68	-$69.68M	-$1.83	N/A

In the previous week, FitLife Brands had 3 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 5 mentions for FitLife Brands and 2 mentions for VistaGen Therapeutics. FitLife Brands' average media sentiment score of 1.01 beat VistaGen Therapeutics' score of 0.93 indicating that FitLife Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FitLife Brands	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

FitLife Brands has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

FitLife Brands has a net margin of 6.64% compared to VistaGen Therapeutics' net margin of -5,487.01%. FitLife Brands' return on equity of 18.31% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 61.4% of FitLife Brands shares are held by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

FitLife Brands currently has a consensus target price of $21.50, suggesting a potential upside of 94.04%. VistaGen Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 35.33%. Given FitLife Brands' stronger consensus rating and higher probable upside, equities research analysts plainly believe FitLife Brands is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

FitLife Brands beats VistaGen Therapeutics on 13 of the 16 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Anixa Biosciences?

VistaGen Therapeutics (NASDAQ:VTGN) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Anixa Biosciences has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. Anixa Biosciences' return on equity of -71.12% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%
Anixa Biosciences	N/A	-71.12%	-62.88%

Anixa Biosciences has lower revenue, but higher earnings than VistaGen Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	22.68	-$69.68M	-$1.83	N/A
Anixa Biosciences	$210K	445.50	-$10.93M	-$0.31	N/A

VistaGen Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

In the previous week, Anixa Biosciences had 2 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 4 mentions for Anixa Biosciences and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.93 beat Anixa Biosciences' score of 0.91 indicating that VistaGen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anixa Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

VistaGen Therapeutics currently has a consensus price target of $0.95, indicating a potential upside of 35.33%. Anixa Biosciences has a consensus price target of $8.50, indicating a potential upside of 209.09%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Anixa Biosciences beats VistaGen Therapeutics on 12 of the 16 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Telomir Pharmaceuticals?

VistaGen Therapeutics (NASDAQ:VTGN) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, VistaGen Therapeutics and VistaGen Therapeutics both had 2 articles in the media. Telomir Pharmaceuticals' average media sentiment score of 1.31 beat VistaGen Therapeutics' score of 0.93 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telomir Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.4% of VistaGen Therapeutics shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Telomir Pharmaceuticals has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Telomir Pharmaceuticals has lower revenue, but higher earnings than VistaGen Therapeutics. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	22.68	-$69.68M	-$1.83	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

VistaGen Therapeutics presently has a consensus price target of $0.95, indicating a potential upside of 35.33%. Given VistaGen Therapeutics' higher possible upside, equities research analysts clearly believe VistaGen Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

VistaGen Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market.

Summary

VistaGen Therapeutics beats Telomir Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get VistaGen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTGN vs. The Competition

Export

Metric	VistaGen Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.80M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-0.38	21.75	25.89	24.17
Price / Sales	22.68	334.18	547.76	101.00
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	0.78	8.31	10.75	6.38
Net Income	-$69.68M	$23.92M	$3.58B	$337.00M
7 Day Performance	9.70%	1.93%	1.97%	-0.20%
1 Month Performance	11.43%	-0.41%	-0.24%	-1.40%
1 Year Performance	-64.37%	65.22%	34.39%	27.76%

VistaGen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTGN VistaGen Therapeutics	2.973 of 5 stars	$0.70 flat	$0.95 +35.3%	-64.4%	$28.80M	$1.27M	N/A	40	Gap Down
ONCY Oncolytics Biotech	2.4159 of 5 stars	$0.92 -4.5%	$8.50 +826.7%	+26.3%	$109.47M	N/A	N/A	30	Gap Down
AADI Aadi Bioscience	N/A	$4.42 +4.7%	N/A	+115.5%	$109.16M	$25.07M	N/A	40	High Trading Volume
FTLF FitLife Brands	4.8942 of 5 stars	$10.83 -3.9%	$21.50 +98.5%	-13.5%	$105.84M	$81.46M	17.93	20	Positive News Gap Up
ANIX Anixa Biosciences	4.3314 of 5 stars	$2.77 -4.8%	$8.50 +206.9%	-14.6%	$99.01M	$210K	N/A	5	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTGN) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. ONCY, AADI, FTLF, ANIX, and TELO

How does VistaGen Therapeutics compare to Oncolytics Biotech?

Summary

How does VistaGen Therapeutics compare to Aadi Bioscience?

Summary

How does VistaGen Therapeutics compare to FitLife Brands?

Summary

How does VistaGen Therapeutics compare to Anixa Biosciences?

Summary

How does VistaGen Therapeutics compare to Telomir Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. ONCY, AADI, FTLF, ANIX, and TELO

How does VistaGen Therapeutics compare to Oncolytics Biotech?

Is VTGN or ONCY more profitable?

Do institutionals & insiders hold more shares of VTGN or ONCY?

Which has more risk & volatility, VTGN or ONCY?

Which has stronger earnings & valuation, VTGN or ONCY?

Does the media refer more to VTGN or ONCY?

Do analysts recommend VTGN or ONCY?

Summary

How does VistaGen Therapeutics compare to Aadi Bioscience?

Does the media refer more to VTGN or AADI?

Which has better valuation & earnings, VTGN or AADI?

Is VTGN or AADI more profitable?

Which has more risk & volatility, VTGN or AADI?

Do analysts rate VTGN or AADI?

Do institutionals and insiders believe in VTGN or AADI?

Summary

How does VistaGen Therapeutics compare to FitLife Brands?

Which has better valuation & earnings, FTLF or VTGN?

Does the media prefer FTLF or VTGN?

Which has more risk and volatility, FTLF or VTGN?

Is FTLF or VTGN more profitable?

Do institutionals and insiders hold more shares of FTLF or VTGN?

Do analysts prefer FTLF or VTGN?

Summary

How does VistaGen Therapeutics compare to Anixa Biosciences?

Is VTGN or ANIX more profitable?

Which has preferable earnings and valuation, VTGN or ANIX?

Which has more risk and volatility, VTGN or ANIX?

Does the media refer more to VTGN or ANIX?

Do insiders & institutionals have more ownership in VTGN or ANIX?

Do analysts recommend VTGN or ANIX?

Summary

How does VistaGen Therapeutics compare to Telomir Pharmaceuticals?

Does the media favor VTGN or TELO?

Do insiders & institutionals believe in VTGN or TELO?

Is VTGN or TELO more profitable?

Which has stronger earnings & valuation, VTGN or TELO?

Do analysts prefer VTGN or TELO?

Which has more volatility & risk, VTGN or TELO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools